Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. Its pipeline includes ERAS-0015 (pan-RAS molecular glue), ERAS-4001 (pan-KRAS inhibitor), and ERAS-12 (EGFR D2/D3 biparatopic antibody). The company targets over five million patients diagnosed annually with RAS/MAPK pathway-driven cancers, pursuing three therapeutic strategies: targeting upstream/downstream nodes, directly targeting RAS, and blocking resistance escape routes.
expected 2026-11-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-104150 | EDGAR | 103K words |
| 2025-03-20 | 2024-12-31 | 0000950170-25-042682 | EDGAR | 107K words |
| 2024-03-27 | 2023-12-31 | 0000950170-24-037193 | EDGAR | 109K words |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009496 | EDGAR | 118K words |
| 2022-03-24 | 2021-12-31 | 0000950170-22-004557 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001193125-26-344611 | EDGAR | 27K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-277625 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001193125-25-178996 | EDGAR | 27K words |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070418 | EDGAR | 23K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125481 | EDGAR | 28K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095437 | EDGAR | 27K words |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055668 | EDGAR | 21K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062094 | EDGAR | 26K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041333 | EDGAR | 25K words |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022282 | EDGAR | 23K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023926 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016907 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-24 | 0001193125-26-361895 | EDGAR | 1K words |
| 2026-08-11 | 0001193125-26-344584 | EDGAR | 3K words |
| 2026-08-10 | 0001193125-26-342669 | EDGAR | 1K words |
| 2026-07-14 | 0001193125-26-303357 | EDGAR | 1K words |
| 2026-07-13 | 0001193125-26-302045 | EDGAR | 2K words |
| 2026-03-12 | 0001193125-26-104105 | EDGAR | 3K words |
| 2026-01-29 | 0001193125-26-029467 | EDGAR | 1K words |
| 2026-01-22 | 0001193125-26-019651 | EDGAR | 1K words |
| 2026-01-20 | 0001193125-26-016556 | EDGAR | 1K words |
| 2026-01-12 | 0001193125-26-009820 | EDGAR | 4K words |
87 total filings indexed. 60 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001761918 |
| Ticker | ERAS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.erasca.com |
| Listed | 2021-07-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ERAS (~200 tokens, structured JSON with cryptographic provenance)